Jody A. Charnow

In an observational study, furosemide doses of 250 to 500 mg and spironolactone doses of 50 to 100 mg were independently associated with approximately 14% and 20% increased odds of hyponatremia, respectively.

Previous retrospective studies have suggested that 5-alpha-reductase inhibitors may beneficial effects on bladder cancer development and/or recurrence, but a prospective cohort study found no protective effect.

Adding furosemide with or without sodium chloride to fluid restriction is not more effective than fluid restriction alone at correcting hyponatremia in patients with the syndrome of inappropriate antidiuresis, a study found.

Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.

Investigators found that men treated with 5-alpha-reductase inhibitors are not more likely to die from prostate cancer or any other cause.